Welcome to the e-CCO Library!

OP25: Prevalence of IBD in the Netherlands: development and validation of machine learning models for administrative data
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Van Linschoten, R.(1,2,3)*;van Leeuwen, N.(2);Hazelzet, J.A.(2);van der Woude, C.J.(3);van Noord, D.(4);West, R.L.(4);
Created: Friday, 14 July 2023, 10:43 AM
OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Dreesen*1, F. Baert2, D. Laharie3, P. Bossuyt4, Y. Bouhnik5, A. Buisson6, G. Lambrecht7, E. Louis8, B. Oldenburg9, B. Pariente10, M. Pierik11, C. J. van der Woude12, G. D’Haens13, S. Vermeire14,15, A. Gils1

Created: Friday, 22 February 2019, 9:41 AM
OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Erwin Dreesen
Created: Tuesday, 28 May 2019, 3:32 PM
Anti-TNF agents, Infliximab, Pharmacokinetics, Treat to target
Files: 1
OP26 The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Iacucci1, S.C. Smith2, A. Bazarova2, U.N. Shivaji1, P. Bhandari3, R. Cannatelli2, M. Daperno4, J.G. Ferraz5, M. Goetz6, X. Gui7, B. Hayee8, G. De Hertogh9, M. Lazarev10, J. Li11, O.M. Nardone2, V. Occhipinti12, R. Panaccione5, A. Parra-Blanco13, L. Pastorelli12, T. Rath14, G. Tontini15, M. Vieth16, V. Villanacci17, D. Zardo18, R. Kiesslich19, R. Bisschops20, S. Ghosh1

Created: Thursday, 30 January 2020, 10:12 AM
OP26: Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
Year: 2022
Source: ECCO'22
Authors: D'Haens, G.(1);Kobayashi, T.(2);Morris, N.(3);Lissoos, T.(3);Hoover, A.(3);Li, X.(3);Arora, V.(3);Milch, C.(3);Sandborn, W.J.(4);Sands, B.E.(5);
Created: Friday, 11 February 2022, 3:52 PM
OP26: Impact of telemonitoring with TECCU on the management of Inflammatory Bowel Disease in Spain: a GETECCU clinical trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Javier Del Hoyo Francisco
Created: Friday, 14 July 2023, 2:22 PM
OP26: Impact of telemonitoring with TECCU on the management of Inflammatory Bowel Disease in Spain: a GETECCU clinical trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Aguas Peris, M.(1,2)*;Del Hoyo, J.(1,2);Vicente, R.(3,4);Barreiro-de Acosta, M.(5);Melcarne, L.(6);Hernández-Camba, A.(7);Alfambra, E.(8,9);Madero, L.(10,11);Sicilia, B.(12);Chaparro, M.(13,14,15,16);Martín-Arranz, M.D.(14,17,18);Pajares, R.(19);Mesonero, F.(20);Mañosa, M.(16,21);Martínez, P.(22);Chacón , S.(23);Tosca, J.(24);Marín, S.(25,26);Sanromán, L.(27,28,29,30);Calvo, M.(31);Monfort, D.(32);Saiz, E.(33);Zabana, Y.(16,34);Guerra, I.(35);Varela, P.(36);Faubel, R.(37,38,39);Corsino, P.(3,4);Porto-Silva, S.(5);Brunet, E.(6);Gutiérrez, A.(10,11,16);Nos, P.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Vermeire1, J-F. Colombel2, B. G. Feagan3, W. J. Sandborn4, B. E. Sands2, S. Danese5, G. D’Haens6, R. Panaccione7, D. T. Rubin8, I. Shafran9, A. Parfionovas10, R. Rogers*10, R. A. Lirio10, E. V. LoftusJr11

Created: Friday, 22 February 2019, 9:41 AM
OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: Final results from the GEMINI LTS study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Remo Panaccione
Created: Tuesday, 28 May 2019, 3:32 PM
Vedolizumab
Files: 1
OP26: Programmable probiotic local delivery of anti-TNF-α nanobody to alleviate DSS-induced colitis
Year: 2024
Source: ECCO'24 Stockholm
Authors: Kang, Guangbo
Created: Tuesday, 30 April 2024, 5:03 PM
OP26: Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Year: 2021
Source: ECCO'21 Virtual
Authors: Schreiber , S.W.(1);Ferrante , M.(2);Panaccione , R.(3);Colombel , J.F.(4);Hisamatsu , T.(5);Lim , A.(6);Lindsay , J.O.(7);Rubin , D.T.(8);Sandborn , W.J.(9);Neimark , E.(10);Song , A.P.(10);Liao , X.(10);Feng , T.(10);Berg , S.(10);Wallace , K.(10);D’Haens , G.R.(11)
Created: Wednesday, 2 June 2021, 4:12 PM
OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Ferrante1, B.G. Feagan2, J. Panés3, F. Baert4, E. Louis5, O. Dewit6, A. Kaser7, W.R. Duan8, D. Gustafson9, X. Liao10, K. Wallace9, J. Kalabic11, G.R. D’Haens12

Created: Thursday, 30 January 2020, 10:12 AM
OP27: A Phase 1 Study Evaluating the Bioequivalence of the Proposed Commercial and Clinical Formulations of Etrasimod 2mg, and the Effect of Food on the Pharmacokinetics of the Proposed Commercial Formulation in Healthy Volunteers
Year: 2022
Source: ECCO'22
Authors: Lee, C.(1);Ramaiya, A.(1);Tang , Y.(1);Sapone, A.(2);Shan , K.(3);Randle, A.(4);Grundy, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
OP27: Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cristina Rubín De Célix
Created: Friday, 14 July 2023, 2:22 PM
OP27: Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Rubín De Célix, C.(1)*;Martín de Carpi, J.(2);Pujol, G.(2);Palomino, L.(3);Velasco, M.(3);Martín-Masot, R.(4);Navas-López, V.M.(4);Ricart, E.(5);Casanova, M.J.(1);Rodríguez Martínez, A.(6);Leo, E.(7);Alcaraz, A.(8);Mañosa, M.(9);Hernández, V.(10);Fernández, R.(10);Sánchez, C.(11);Menchén, L.(12);Mesonero, F.(13);Barreiro-De Acosta, M.(14);Martinon, N.(15);Tejido Sandoval, C.(16);Rendo Vázquez, A.(17);Corsino, P.(18);Vicente, R.(18);Hernández-Camba, A.(19);Alberto Alonso, J.R.(20);Alonso-Abreu, I.(21);Castro Millán, A.M.(22);Peries Reverter, L.(23);Castro, B.(24);Fernández-Salgado, E.(25);Busto Cuiñas, M.M.(26);Benítez, J.M.(27);Madero, L.(28);Clemente, F.(29);Riestra, S.(30);Jiménez-Treviño, S.(31);Boscá, M.(32);Chaparro, M.(1);Gisbert, J.P.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP27: Has been withdrawn
Year: 2021
Source: ECCO'21 Virtual
Authors: Has been withdrawn
Created: Wednesday, 2 June 2021, 4:12 PM
OP27: High-dimensional mass cytometry reveals the immune cell landscape in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. van Unen1, N. Li1, T. Abdelaal2,3, Y. Kooy-Winkelaar1, L. Ouboter*1,4, G. Beyrend1, T. Höllt3,6, L. Mearin7, A. Witte8, H. Escher9, B. Lelieveldt10,11, A. van der Meulen - de Jong4, F. Koning1

Created: Friday, 22 February 2019, 9:41 AM